Proteomics International’s share price surged as much as 24 per cent today on the best volume in more than two months to reach 75 cents, driven by news of successful study results from its game-changing PromarkerEndo blood test being developed to diagnose endometriosis.
In a significant breakthrough in women’s health, the innovative diagnostic tool has proven it is highly accurate in differentiating between healthy individuals and those suffering endometriosis, a chronic condition affecting one in nine women worldwide.
